scispace - formally typeset
D

Daniel Prieto-Alhambra

Researcher at University of Oxford

Publications -  438
Citations -  11189

Daniel Prieto-Alhambra is an academic researcher from University of Oxford. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 45, co-authored 345 publications receiving 7269 citations. Previous affiliations of Daniel Prieto-Alhambra include Erasmus University Medical Center & Mount Vernon Hospital.

Papers
More filters
Journal ArticleDOI

Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self‐Controlled Case Series in the United Kingdom

TL;DR: This study found a 50% to 65% increased risk of AKI associated with BP use in elderly patients with complex health needs, and future studies should further investigate the risk–benefit of BP Use in these patients.
Journal ArticleDOI

Mortality rates at 10 years after metal-on-metal hip resurfacing compared with total hip replacement in England

TL;DR: Patients in England with hip osteoarthritis who underwent MoM hip resurfacing between 1999 and 2012 have reduced long term mortality compared with those who underwent cemented and uncemented THR.
Posted ContentDOI

Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis

TL;DR: Comorbidities that were more prevalent with CO VID-19 hospitalization (compared to COVID-19 diagnosed) in pregnancy included renal impairment and anemia, and despite low fatality, pregnancy and maternal outcomes were worse in COvid-19 than influenza.
Journal ArticleDOI

AI-related BMD variation in actual practice conditions: A prospective cohort study.

TL;DR: A clinically relevant bone loss associated with AI therapy amongst nonusers of preventative BPs is confirmed, and the importance of BMD monitoring as well as calcium and 25-hydroxy vitamin D supplementation in these patients is reported on.
Journal ArticleDOI

Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study.

TL;DR: Patients with gout from a primary prevention population with a low-to-intermediate incidence of CHD should be evaluated according to their cardiovascular risk assessment, lifestyle recommendations, and preferences, in line with recent European League Against Rheumatism recommendations.